Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX.
We investigated the antitumoral activity of Dabis Maleate given on different dosage schedules and as continuous infusion in a murine reticular cell sarcoma M5076 (M5) and in a subline made resistant to cyclophosphamide and other nitrogen mustards (M5/CTX). The therapeutic index of Dabis Maleate was clearly better when the drug was given as a continuous 72-h infusion. Dabis Maleate appeared non-cross-resistant to cyclophosphamide and this property renders it interesting for further clinical development.
Tagliabue
G
G
Istituto di Ricerche Farmacologiche M.Negri, Milan, Italy.
Filippeschi
S
S
Hendricks
H
H
D'Incalci
M
M
D000818:Animals; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002455:Cell Division / Q000187:drug effects; D003520:Cyclophosphamide / Q000494:pharmacology*; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D000644:Quaternary Ammonium Compounds; C072879:NSC 262266; D003520:Cyclophosphamide